Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02721485
Other study ID # 20150619-01H
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2016
Est. completion date January 13, 2018

Study information

Verified date September 2018
Source Ottawa Hospital Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Salt fluids are used extensively for acutely ill patients who are admitted to hospital. Two salt fluids commonly used are Normal Saline and Ringer's Lactate. Both are used to rehydrate patients, restore fluid volume and help stabilize blood pressure and failing organs. Both salt fluids have been used for several decades. Until recently, it was thought the fluids are essentially equivalent other than some minor differences related to the concentration of salt components (sodium and chloride) and buffers (Ringer's Lactate has lactate as a buffer). Recent data suggest that salt fluids containing less chloride like the Ringer's Lactate, cause less acid in the blood, less kidney failure, and less death. However, the studies to date are small and weak in their design and it is possible that there are no important differences that affect patients. Hence, the research team will conduct a robust pragmatic clinical trial where several academic and community hospitals will be randomized to use either Ringer's Lactate only or Normal Saline only for a period of three months. The trial will yield high quality and robust data to determine if Ringers Lactate reduces death and re-admissions to hospital. Before embarking on this large-scale trial, it is important to conduct a smaller (pilot) trial to evaluate if the larger trial will be feasible and not too costly. In this small trial involving no less than 4 hospitals, the investigators will determine how well the fluid interventions are adhered to in each hospital, record how long it takes to receive approval from research ethics boards and be ready to start the study. The investigators will also record challenges and develop solutions related to the operations of the trial, and describe important clinical and outcome data essential for the design and planning of the large trial.


Description:

Other than the administration of oxygen, crystalloid resuscitation fluids are the most common intervention administered to the majority of hospitalized patients. These fluids may be used as a life saving measure to re-establish hemodynamic stability, for rehydration, and to replace losses and maintain intravascular volume in the surgical setting. In the province of Ontario alone, approximately 1 million patients per year will receive one or both of these resuscitation fluids during their hospital admission. The two most common usual care resuscitation crystalloid fluids are Normal Saline and Ringer's Lactate and until recently there was no evidence to suggest that one crystalloid fluid was clinically superior to the other. However, the safety of Normal Saline is now being questioned due to its high chloride content and its association with the development of hyperchloremic metabolic acidosis. Studies in healthy volunteers and observational studies in the critically ill and surgical patient populations have associated saline with an increased risk of acute renal injury and requirement for dialysis, post-operative infections, death and increased resource and blood transfusion use. The evidence base is currently weak given that the majority of studies are observational and suffer from methodological weaknesses including confounding by indication, selection bias, and inability to disentangle the effects of a specific fluid due to interaction of co-interventions administered. As such, several authors and editorials have called for adequately powered randomized controlled trials with clinically relevant outcomes to determine if Ringer's Lactate is indeed superior to Normal Saline for resuscitation.

Given their widespread use, small differences in clinical outcomes between crystalloid resuscitation fluids are highly relevant. Furthermore, small absolute differences in important clinical outcomes translate into significant savings to hospitals and the health care system. To illustrate, if death and hospital re-admissions were each reduced by an absolute 0.5%, this would translate to approximately 2500 lives saved and savings of 10 million dollars to the Ontario health care system. Hence, in collaboration with the Canadian Critical Care Trials Group, the Crystalloid FLUID Choices for Hospitalized Patients (FLUID) trial will examine whether Ringer's Lactate as compared to Normal Saline reduces clinically important outcomes such as death, and hospital re-admissions - outcomes that are particularly relevant to hospitals and the health care system. This proposal is a large pragmatic cluster cross-over comparative effectiveness trial that will be conducted in both academic and community centres in Ontario. It will involve waivers of consent and a novel design making use of provincially available health administrative data through the Institute of Clinical Evaluative Sciences (ICES) to facilitate all data collected in the trial. The trial will answer this fundamental fluid resuscitation question with much less cost in comparison to an individual patient randomized controlled trial. It will help build expertise and capacity for future trials of similar design in the province of Ontario and throughout Canada. However, prior to embarking on a large-scale trial, it is imperative to conduct a pilot trial to determine feasibility and optimize the trial design.


Recruitment information / eligibility

Status Completed
Enrollment 30000
Est. completion date January 13, 2018
Est. primary completion date January 13, 2018
Accepts healthy volunteers No
Gender All
Age group N/A to 100 Years
Eligibility Inclusion Criteria:

- All patients admitted to the participating hospitals for the first time in the last 90 days (index admission) over the duration of the study period.

Exclusion Criteria:

- Neonates (< 30 days)

- Physicians may also opt out of the use of the allocated study fluid for individual patients if there is a strong preference to do so.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Ringer's Lactate
After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
Normal Saline
After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.

Locations

Country Name City State
Canada Hamilton General Hospital Hamilton Ontario
Canada Ottawa Hospital Civic Campus Ottawa Ontario
Canada Queensway Carleton Hosptial Ottawa Ontario
Canada The Ottawa Hospital General Campus Ottawa Ontario

Sponsors (1)

Lead Sponsor Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility: adherence to protocol Compliance defined as at least 80% of the prescribed study fluid being administered in the participating hospitals over the 2, 3-month study periods. Up to six months
Primary Feasibility: time to research ethics board approval Compliance defined as taking no longer than 3 months to achieve Up to three months
Primary Feasibility: readiness to initiate protocol Compliance defined as taking no longer than 3 months after ethics approval Up to three months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06351475 - Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy N/A
Not yet recruiting NCT04982016 - Effects of Fluid Therapy on Microcirculatory Reactivity N/A
Completed NCT03215797 - Phenylephrine or Norepinephrine for a Better Hemodynamic Stability Phase 3
Completed NCT04536324 - The Absorption Rate of Subcutaneous Infused Fluid
Completed NCT02977390 - Passive Leg Raise Induced Stroke Volume Changes in Elderly Prior to Elective Surgery Measured by LiDCOplusTM N/A
Recruiting NCT01415284 - ED50 Determination of Hydroxyethylstarch for Treatment of Hypotension During Cesarean Section Under Spinal Anesthesia Phase 4
Completed NCT03245372 - Goal Directed Therapy Versus Standard Care in Lung Resection Surgery (GDT-thorax Study). N/A
Recruiting NCT05606536 - The Impact of Intra-operative Fluid Infusion Rate on Microcirculation N/A
Terminated NCT03553394 - Effects of Restrictive Fluid Strategy on Postoperative Oliguric Pancreatic Surgery Patients N/A
Recruiting NCT05153837 - Effect of Oral Water in Healthy Volunteers on Cardiac Output, Regional Flow and Microcirculation in Healthy Volunteers N/A
Completed NCT03323580 - Effects of Intraoperative GDFT on the Postoperative Brain Edema N/A
Completed NCT03394833 - Hemodynamic Stability During Induction of Anaesthesia N/A
Completed NCT03280953 - Assessing Fluid Responsiveness With PWTT
Not yet recruiting NCT06256120 - Effect of Fluid Regimen on Acute Kidney Injury N/A
Recruiting NCT03178578 - A Prospective Observational Study of the Expectations and Physiological Effects of Fluid Bolus Therapy
Enrolling by invitation NCT04388995 - SVV and PPV Predict Fluid Responsiveness in Mechanically Ventilated Elderly Patients Under General Anesthesia N/A
Not yet recruiting NCT06396884 - Hemodynamic Optimization During Spinal Anesthesia in the Elderly
Recruiting NCT05369559 - Mini Bolus for Fluid Challenge Responsiveness in the Emergency Department Early Phase 1
Recruiting NCT05054452 - Predicting Fluid Responsiveness in Mechanically Ventilated Critically Ill Children Using Transthoracic Echocardiography N/A
Completed NCT03060408 - Comparison of Fluid Requirements in Pancreatectomy: Laparotomy vs. Laparoscopy N/A